Journal article
Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia
Dean G Campelj, Cara A Timpani, Tabitha Cree, Aaron C Petersen, Alan Hayes, Craig A Goodman, Emma Rybalka
PHARMACEUTICALS | MDPI | Published : 2021
DOI: 10.3390/ph14050478
Abstract
Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in cancer and chemotherapy-induced cachexia. Here, we investigate the effects of a chemotherapeutic agent, 5-fluorouracil (5FU), on skeletal muscle mass and function, and whether small-molecule therapeutic candidate, BGP-15, could be protective against the chemotoxic challenge exerted by 5FU. Additionally, we explore the molecular signature of 5FU treatment. Male Balb/c mice received metronomic tri-weekly intraperitoneal delivery of 5FU (23 mg/kg), with and without BGP-15 (15 mg/kg), 6 times in total over a 15 day treatment period. We demonstrated that neither 5FU, nor 5FU combined with BGP-15, affected body ..
View full abstractGrants
Funding Acknowledgements
This study was funded by the former Institute of Sport, Exercise and Active Living, and Centre for Chronic Disease, program grants (both Victoria University).